Dexmedetomidine vs Propofol in High-Risk ERCP Patients

ERCP requires deep sedation due to pain and discomfort, but propofol-commonly used with opioids-often causes respiratory and cardiovascular complications, especially in elderly or high-risk patients. Dexmedetomidine offers sedation without respiratory depression but may lower blood pressure and heart rate. Current monitoring often relies only on SpO₂, while capnography and the Integrated Pulmonary Index (IPI) provide earlier detection of respiratory events but are underused in ERCP studies. This study compares dexmedetomidine and propofol in high-risk ERCP patients, focusing on respiratory and hemodynamic effects, propofol consumption, recovery, and discharge times. The hypothesis is that dexmedetomidine will cause fewer adverse respiratory and hemodynamic effects.

NCT Number	NCT07166614
Lead Sponsor	Sisli Hamidiye Etfal Training and Research Hospital
Conditions	Respiratory Depression, Hypoxemia, Hypotension Drug-Induced, Bradycardia
Enrollment	100 participants
Start Date	2025-09-03
Primary Completion	2026-02-28 (estimated)
Study Completion	2026-04-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-11